Health Technology/clinical-trials

Randomised Trial Opens: Digital Lifestyle Education vs Usual Care in HFpEF With Obesity — The ELITE-HFpEF Study Explained

247 Health News Editorial

·

7 July 2026

·

4 min read

·clinical-trials

The ELITE-HFpEF trial is a randomised study testing whether a six-month digital lifestyle education program — covering exercise, nutrition, and stress management — can improve peak oxygen uptake in patients with HFpEF and overweight or obesity. Sponsored by the Maimónides Biomedical Research Institute of Córdoba, the trial targets a high-burden, undertreated phenotype where pharmacological options remain limited. Results are anticipated by late 2028.

Originally reported by ClinicalTrials.gov

References

  1. 1.Maimónides Biomedical Research Institute of Córdoba (IMIBIC). (2025). Randomized trial of a digital lifestyle education strategy in patients with heart failure and overweight or obesity: The ELITE-HFpEF study (NCT07661732). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07661732
  2. 2.Pandey, A., Parashar, A., Kumbhani, D. J., Agarwal, S., Garg, J., Kitzman, D., Levine, B. D., Drazner, M., & Berry, J. D. (2015). Exercise training in patients with heart failure and preserved ejection fraction: Meta-analysis of randomized control trials. Circulation: Heart Failure, 8(1), 33–40. https://doi.org/10.1161/CIRCHEARTFAILURE.114.001615
  3. 3.Kitzman, D. W., Brubaker, P., Morgan, T., Haykowsky, M., Hundley, G., Kraus, W. E., Eggebeen, J., & Nicklas, B. J. (2016). Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction. JAMA, 315(1), 36–46. https://doi.org/10.1001/jama.2016.0022
  4. 4.Lam, C. S. P., Roger, V. L., Rodeheffer, R. J., Borlaug, B. A., Enders, F. T., & Redfield, M. M. (2011). Pulmonary hypertension in heart failure with preserved ejection fraction: A community-based study. Journal of the American College of Cardiology, 57(10), 1313–1319. https://doi.org/10.1016/j.jacc.2011.03.037
  5. 5.Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner-La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., Giannetti, N., Gomez-Mesa, J. E., Janssens, S., Januzzi, J. L., González-Juanatey, J. R., Merkely, B., Nicholls, S. J., Perrone, S. V., Piña, I. L., … Packer, M. (2021). Empagliflozin in heart failure with a preserved ejection fraction. New England Journal of Medicine, 385(16), 1451–1461. https://doi.org/10.1056/NEJMoa2107038
  6. 6.McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., Cleland, J. G. F., Coats, A. J. S., Crespo-Leiro, M. G., Farmakis, D., Gilard, M., Heymans, S., Hoes, A. W., Jaarsma, T., Jankowska, E. A., … ESC Scientific Document Group. (2021). 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 42(36), 3599–3726. https://doi.org/10.1093/eurheartj/ehab368
Share:XLinkedIn
2

247 Health News Editorial

247 Health News is a medical intelligence platform delivering evidence-based research appraisals, clinical trial monitoring, and health technology news for healthcare professionals.

This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service